166 related articles for article (PubMed ID: 27207511)
1. Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior.
Schlögl H; Müller K; Horstmann A; Miehle K; Püschel J; Villringer A; Pleger B; Stumvoll M; Fasshauer M
Diabetes; 2016 Aug; 65(8):2179-86. PubMed ID: 27207511
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment.
Püschel J; Miehle K; Müller K; Villringer A; Stumvoll M; Fasshauer M; Schlögl H
Cytokine; 2019 Jan; 113():400-404. PubMed ID: 30539782
[TBL] [Abstract][Full Text] [Related]
3. Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy.
Schlögl H; Villringer A; Miehle K; Fasshauer M; Stumvoll M; Mueller K
J Endocr Soc; 2023 Jul; 7(8):bvad072. PubMed ID: 37404242
[TBL] [Abstract][Full Text] [Related]
4. Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy.
Vieira DB; Antel J; Peters T; Miehle K; Stumvoll M; Hebebrand J; Schlögl H
Obes Facts; 2022; 15(5):685-693. PubMed ID: 36037795
[TBL] [Abstract][Full Text] [Related]
5. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
6. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
Miehle K; Stumvoll M; Fasshauer M; Hierl T
Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
[TBL] [Abstract][Full Text] [Related]
7. Long-term stabilization effects of leptin on brain functions in a leptin-deficient patient.
Frank S; Heni M; Moss A; von Schnurbein J; Farooqi S; Häring HU; Fritsche A; Preissl H; Wabitsch M
PLoS One; 2013; 8(6):e65893. PubMed ID: 23799059
[TBL] [Abstract][Full Text] [Related]
8. Reward Processing During Monetary Incentive Delay Task After Leptin Substitution in Lipodystrophy-an fMRI Case Series.
Schlögl H; Janssen L; Fasshauer M; Miehle K; Villringer A; Stumvoll M; Mueller K
J Endocr Soc; 2023 May; 7(6):bvad052. PubMed ID: 37180211
[TBL] [Abstract][Full Text] [Related]
9. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.
McDuffie JR; Riggs PA; Calis KA; Freedman RJ; Oral EA; DePaoli AM; Yanovski JA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4258-63. PubMed ID: 15356018
[TBL] [Abstract][Full Text] [Related]
10. Metreleptin: first global approval.
Chou K; Perry CM
Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
[TBL] [Abstract][Full Text] [Related]
11. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy.
Aotani D; Ebihara K; Sawamoto N; Kusakabe T; Aizawa-Abe M; Kataoka S; Sakai T; Iogawa H; Ebihara C; Fujikura J; Hosoda K; Fukuyama H; Nakao K
J Clin Endocrinol Metab; 2012 Oct; 97(10):3663-71. PubMed ID: 22872692
[TBL] [Abstract][Full Text] [Related]
12. Leptin therapy alters appetite and neural responses to food stimuli in brain areas of leptin-sensitive subjects without altering brain structure.
Farr OM; Fiorenza C; Papageorgiou P; Brinkoetter M; Ziemke F; Koo BB; Rojas R; Mantzoros CS
J Clin Endocrinol Metab; 2014 Dec; 99(12):E2529-38. PubMed ID: 25279500
[TBL] [Abstract][Full Text] [Related]
13. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
14. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
15. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
17. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
18. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
19. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
20. Update on Therapeutic Options in Lipodystrophy.
Akinci B; Meral R; Oral EA
Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
